In vitro susceptibility of six fluoroquinolones against invasive Streptococcus pneumoniae isolated from 1996 to 2001 in Taiwan

Microbial Drug Resistance

Volumn 9, Issue 2, 2003, Pages 211-217

  Chen, J Y ^a   Fung, C P ^b   Wang, C C ^c   Chu, M L ^c   Siu, L K ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Dept of Orthopaedics   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DNA; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; DNA SEQUENCE; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TAIWAN;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0038274555     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/107662903765826813     Document Type: Article

References (32)

1. Anonymous. 1984. Update: pneumococcal polysaccharide vaccine usage - United States. MMWR Morb. Mortal. Wkly. Rep. 33:273-6, 281.
2. Bachoual, R., J. Tankovic, and C.J. Soussy. 1998. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli. Microb. Drug Resist. 4:271-276.
3. Black, S.B., H.R. Shinefield, S. Ling, J. Hansen, B. Fireman, D. Spring, J. Noyes, E. Lewis, P. Ray, J. Lee, and J. Hackell. 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21:810-815.
4. Breiman, R.F., J.C. Butler, F.C. Tenover, J.A. Elliott, and R.R. Facklam. 1994. Emergence of drug-resistant pneumococcal infections in the United States. J. Am. Med. Assn. 271:1831-1835.
5. Brenwald, N.P., M.J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
6. Brueggemann, A.B., S.L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G.V. Doern. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46:680-688.
7. Chen, D.K., A. McGeer, J.C. de Azavedo, and D.E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341:233-239.
8. Chiou, C.C., Y.C. Liu, T.S. Huang, W.K. Hwang, J.H. Wang, H.H. Lin, M.Y. Yen, and K.S. Hsieh. 1998. Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan. J. Clin. Microbiol. 36:1933-1937.
9. Dalhoff, A., C. Krasemann, S. Wegener, and G. Tillotson. 2001. Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity. Clin. Infect. Disc. 32(Suppl 1):S22-9.
10. Doern, G.V., K.P. Heilmann, H.K. Huynh, P.R. Rhomberg, S.L. Coffman, and A.B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.
11. Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, R. Kohberger, G. Siber, and P.H. Makela. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
12. Fung, C.P., B.S. Hu, S.C. Lee, P.Y. Liu, T.N. Jang, H.S. Len, B.I. Kuo, M.Y. Yen, C.Y. Liu, Y.C. Liu, Y.J. Lau, and K.W. Yu. 2000. Antimicrobial resistance of Streptococcus pneumoniae isolated in Taiwan: an island-wide surveillance study between 1996 and 1997. J. Antimicrob. Chemother. 45:49-55.
13. Gable, C.B., S.S. Holzer, L. Engelhart, R.B. Friedman, F. Smeltz, D. Schroeder, and K. Baum. 1990. Pneumococcal vaccine. Efficacy and associated cost savings. J. Am. Med. Assn. 264:2910-2915.
14. Heaton, V.J., C.E. Goldsmith, J.E. Ambler, and L.M. Fisher. 1999. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Antimicrob. Agents Chemother. 43:2998-3000.
15. Heffelfinger, J.D., S.F. Dowell, J.H. Jorgensen, K.P. Klugman, L.R. Mabry, D.M. Musher, J.F. Plouffe, A. Rakowsky, A. Schuchat, and C.G. Whitney. 2000. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. 160:1399-1408.
16. Hsueh, P.R., Y.C. Liu, J.M. Shyr, T.L. Wu, J.J. Yan, J.J. Wu, H.S. Len, Y.C. Chuang, V.J. Lau, and K.T. Luh. 2000. Multi-center surveillance of antimicrobial resistance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan during the 1998-1999 respiratory season. Antimicrob. Agents Chemother. 44:1342-1345.
17. Hsueh, P.R., L.J. Teng, T.L. Wu, S.W. Ho, and K.T. Luh. 2001. First clinical isolate of Streptococcus pneumoniae exhibiting high-level resistance to fluoroquinolones in Taiwan. J. Antimicrob. Chemother. 48:316-317.
18. Hudspeth, M.K., T.C. Smith, C.P. Barrozo, A.W. Hawksworth, M.A. Ryan, and G.C. Gray. 2001. National Department of Defense Surveillance for Invasive Streptococcus pneumoniae: antibiotic resistance, serotype distribution, and arbitrarily primed polymerase chain reaction analyses. J. Infect. Dis. 184:591-596.
19. Jette, L.P., G. Delage, L. Ringuette, R. Allard, P. De Wals, F. Lamothe, and V. Loo. 2001, Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J. Clin. Microbiol. 39:733-737.
20. Johnson, A.P., M. Warner, R.C. George, and D.M. Livermore. 2001. Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales. J. Antimicrob. Chemother. 47:411-415.
21. Johnson, A.P., M. Warner, and D.M. Livermore. 2001. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance. Int. J. Antimicrob. Agents 17:377-381.
22. Jones, M.E., A.M. Staples, I. Critchley, C. Thornsberry, P. Heinze, H.D. Engler, and D.F. Sahm. 2000. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob. Agents Chemother. 44:2645-2652.
23. Kaplan, S.L., and E.O. Mason, Jr. 1998. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin. Microbiol. Rev. 11:628-644.
24. Klyachko, K.A., S. Schuldiner, and A.A. Neyfakh. 1997. Mutations affecting substrate specificity of the Bacillus subtilis multidrug transporter Bmr. J. Bacteriol. 179:2189-2193.
25. Lu, C.Y., P.I. Lee, P.R. Hsueh, S.C. Chang, T.F. Chin, H.C. Lin, C.Y. Lee, and L.M. Huang. 1999. Penicillin-nonsusceptible Streptococcus pneumoniae infections in children. J. Microbiol. Immunol. Infect. 32:179-186.
26. National Committee for Clinical Laboratory Standards. 2000. Performance standards for dilution antimicrobial suscepfibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, PA.
27. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing: Twelfth information supplement. (M100-S12). National Committee for Clinical Laboratory Standards, Villanova, PA.
28. Neyfakh, A.A., C.M. Borsch, and G.W. Kaatz. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128-129.
29. Piddock, L.J., M.M. Johnson, S. Simjee, and L. Pumbwe. 2002. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:808-812.
30. Saravolatz, L., O. Manzor, C. Check, J. Pawlak, and B. Belian. 2001. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. 47:875-877.
31. Siu, L.K., M.L. Chu, M. Ho, Y.S. Lee, and C.C. Wang. 2002. Epidemiology of invasive pneumococcal infection in Taiwan: antibiotic resistance, serogroup distribution, and ribotypes analyses. Microb. Drug Resist. 8:201-208.
32. Whitney, C.G., M.M. Farley, J. Hadler, L.H. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P.R. Cieslak, M. Cetron, E.R. Zell, J.H. Jorgensen, and A. Schuchat. 2000. Increasing prevalence of multidrug resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924.